Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WVE-004 open-label extension in C9orf72-associated ALS and/or FTD
NL-OMON53682Active, not recruiting
- Sponsor
- Wave Life Sciences
- Start
- Nov 2022
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Open-label trial of WVE-004 in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), sponsored by Wave Life Sciences. Primary endpoint: Incidence of adverse events. Started Nov 2022; status: active, not recruiting.
02
Drugs
WVE-004
03
Conditions
amyotrophic lateral sclerosis (ALS)frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NL-OMON53682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53682.